Trial Profile
A Phase 1 Study to Evaluate the Safety of OBP-301, Telomelysin in Combination With Radiation Therapy in Patients With Esophageal Cancer Not Applicable for Standard Therapy
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Mar 2023
Price :
$35
*
At a glance
- Drugs Suratadenoturev (Primary)
- Indications Adenocarcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Oncolys BioPharma
- 10 Feb 2023 According to a Oncolys Biopharma media release, this trial is being conducted on the basis of orphan drug designation of Telomelysin for esophageal cancer in the U.S.
- 18 Jun 2021 Results assessing the safety and clinical benefit of OBP-301 plus radiotherapy oesophageal cancer patients unfit for standard chemoradiation treatments, published in the European Journal of Cancer.
- 24 Sep 2018 Planned End Date changed from 1 Oct 2018 to 1 Jun 2019.